Answers are grounded in this paper and cite their sources.
Clonidine (Catapres), a new imidazoline derivative with antihypertensive properties, was administered parenterally to 20 hypertensive patients. Thirteen patients with stable hypertension received clonidine electively. After a brief pressor phase, the patients with stable hypertension had a good antihypertensive response (a 17% average reduction in mean arterial pressure from 139 ± 11 to 115 ± 12 mm Hg). In 7 patients with accelerated hypertension who received clonidine intravenously, the pressor phase was of greater magnitude, lasted for a longer period of time, and was not associated with an antihypertensive response. It is concluded that transferring drug‐response data from patients with stable hypertension to those in an accelerated phase and vice versa may give erroneous impressions. Since the major need for a parenteral antihypertensive drug is for the therapy of hypertensive crises, the usefulness of intravenous clonidine appears limited.
No takes yet. Share an insight, caveat, or question.
Mroczek et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: